

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

GROUP: 1626

Thomas RUECKLE, et al.

SERIAL NO: 10/565,976

EXAMINER: HAVLIN, R.

FILED: April 28, 2006


FOR: 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS
P13 KINASE IHIBITORS

RESTRICTION RESPONSE AND AMENDMENT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated June 19, 2008, Applicants elect, with traverse, Group I, Claims 1–11 and 21, for examination. Applicants provisionally elect, for examination purposes only and without traverse, specie N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-benzenesulfonamide, corresponding to Example 8 on page 47 of the specification (reproduced below). In the elected specie, which encompasses at least Claims 1, 2, 4, 5, 7, 8, 11, and 21, A is 2H-(benzo-1,3-dioxolanyl), R¹ and R² are hydrogen atoms, X is a sulfur atom, Y is an oxygen atom, G is phenyl sulfonyl.



Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.

Support for Amended Claims begins on page 14 of this paper.

Remarks/Arguments begin on page 15 of this paper.